🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

TransMedics Group, Inc. TMDX R2K

Healthcare · Medical Devices · United States
https://www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

READ MORE ›
$67.20
-47.14% 1Y

Market & Price

Market Cap
$2.32B
Current Price
$67.20
High / Low (52W)
$150.42 / $62.04
Beta
2.06

Valuation

Stock P/E
15.38
Industry PE
23.65
Forward P/E
18.91
PEG Ratio
-
Book Value
$13.81
Price to Book
4.87
P/S
3.65
EV/EBITDA
21.73
Dividend Yield
-

Profitability & Returns

ROCE
12.39%
ROE
45.22%
ROA
5.20%
Profit Margin
27.04%
Op Margin
7.65%
EPS (Latest Qtr)
$0.20
EPS (TTM)
$4.37

Balance Sheet & Liquidity

Debt/Equity
1.75
Quick Ratio
6.01
Current Ratio
6.74
Debt
$863.41M
Total Assets
$1.07B
Current Assets
$637.78M
Working Capital
$548.48M

Ownership

Promoter Holding
3.40%
Chg in Prom Hold
-
FII / Inst Holding
108.87%
Chg in FII Hold
0.05%

Financial Snapshot

Enterprise Value
$2.72B
Total Revenue (TTM)
$635.89M
EBITDA
$125.35M
Free Cash Flow
$108.82M
Operating Cash Flow
$220.23M
Shares Outstanding
34.56M
Gross Margin
59.09%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
86.42%
Profit 5Y
208.41%
Revenue (YoY)
21.20%
Earnings (YoY)
-71.50%

PROS

  • Strong return on equity of 45.2%.
  • Excellent profit margin of 27.0%.
  • Compounding revenue at 86.4% over 5 years.
  • Profit CAGR of 208.4% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 55.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TMDX TransMedics Group, Inc. R2K 67.20 15.38 $2.32B - 12.39% 45.22% 86.42% 208.41%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 2.76M3.26M4.75M-5.29M6.21M7.88M-8.24M3.92M7.97M-7.64M8.67M5.41M15.88M20.52M24.30M------143.54M157.37M143.82M160.76M173.93M
Cost of Revenue ------------------------55.31M60.78M59.25M67.35M72.77M
Gross Profit 924.00K1.18M2.13M1.50M2.57M3.33M4.22M3.74M4.86M1.91M5.04M4.83M4.81M5.59M3.77M12.10M14.35M18.11M28.77M36.74M40.66M59.96M69.26M-88.23M96.59M84.58M93.41M101.16M
Operating Expenses ------------------------60.78M60.02M61.27M72.14M87.86M
Operating Income -4.78M-5.16M-3.94M-6.36M-5.96M-7.71M-7.24M-8.69M-8.02M-7.86M-4.61M-5.90M-6.51M-9.87M-11.72M-9.37M-9.74M-5.54M-2.09M-906.00K-28.34M12.42M12.51M-27.44M36.57M23.30M21.27M13.30M
EBITDA ------------------------36.27M46.39M33.37M32.45M27.52M
Interest Expense ------------------------3.46M3.48M3.49M3.35M7.17M
Pretax Income ------------------------26.68M36.18M23.03M21.63M8.48M
Tax Provision ------------------------994.00K1.27M-1.29M-83.75M1.17M
Net Income -4.90M-6.12M-5.11M-7.63M-6.89M-9.20M-8.28M-9.18M-8.85M-8.50M-5.09M-6.31M-7.92M-10.67M-12.96M-10.56M-11.52M-7.43M-2.64M-1.00M-25.42M12.20M12.19M-25.68M34.91M24.32M105.38M7.32M
Diluted EPS ---------0.42-0.36-0.19--0.29-0.39-0.47-0.38-0.41-0.25-0.08-0.03-0.780.350.35-0.700.920.662.620.20
R&D Expense 3.46M3.43M3.27M-3.88M4.79M4.94M-6.22M3.90M4.16M-4.53M6.29M5.16M7.53M6.71M6.81M5.87M8.29M11.13M11.38M13.86M14.27M17.16M15.93M15.26M-24.88M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 14.66M25.84M28.36M-93.46M241.62M441.54M605.49M
Cost of Revenue ----28.19M87.53M179.46M242.69M
Gross Profit 5.73M13.86M16.64M-65.27M154.09M262.08M362.81M
Operating Expenses ----96.71M182.82M224.59M254.22M
Operating Income -20.24M-29.60M-26.38M--31.44M-28.73M37.50M108.58M
EBITDA -----28.96M-7.70M69.95M148.49M
Interest Expense ----3.73M10.79M14.41M13.78M
Pretax Income -----36.16M-26.67M35.78M107.52M
Tax Provision ----66.00K-1.64M316.00K-82.77M
Net Income -23.76M-33.55M-28.75M--36.23M-25.03M35.46M190.29M
Diluted EPS ---1.16--1.23-0.771.074.87
R&D Expense 13.66M19.87M18.83M22.30M26.81M36.05M55.97M69.06M

Compounded Sales Growth

5 Years:86.42%
1 Year:21.20%

Compounded Profit Growth

5 Years:208.41%
1 Year:-71.50%

Stock Price Performance

1 Year:-47.14%
6 Months:-53.97%
3 Months:-53.74%
1 Month:-31.83%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -42.16M105.30M152.03M-277.15M706.05M804.08M1.07B
Current Assets -----252.29M510.65M497.22M637.78M
Cash & Equivalents -20.24M20.09M24.58M-201.18M394.81M336.65M488.37M
Inventory -----20.61M44.23M46.55M48.88M
Receivables -----27.61M63.58M97.72M84.28M
Total Liabilities -47.88M50.65M48.13M-89.77M568.85M575.47M595.27M
Current Liabilities -12.55M16.11M11.88M-23.66M54.93M59.91M89.31M
Long Term Debt -33.67M34.15M34.66M-58.70M506.20M509.31M502.39M
Total Debt -----67.56M515.95M518.29M519.28M
Total Equity -168.72M-192.24M54.65M103.89M-187.38M137.20M228.60M473.10M
Shares Outstanding -----32.14M32.67M33.62M34.27M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -25.98M-32.29M-30.27M--45.82M-13.03M48.80M192.84M
Investing Cash Flow 12.31M-60.50M-41.60M-54.51M-193.95M-129.30M-59.25M
Financing Cash Flow 22.06M92.72M75.55M-167.93M400.42M22.87M16.86M
Capital Expenditure -418.00K-165.00K-455.00K--11.91M-179.06M-129.74M-59.25M
Free Cash Flow -26.40M-32.45M-30.72M--57.72M-192.09M-80.94M133.59M
Net Change in Cash ----176.62M193.44M-57.63M150.45M

Ratios (Annual)

Figures in %.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 39.1%53.6%58.7%-69.8%63.8%59.4%59.9%
Operating Margin % -138.1%-114.5%-93.0%--33.6%-11.9%8.5%17.9%
Net Margin % -162.1%-129.8%-101.4%--38.8%-10.4%8.0%31.4%
ROE % 12.4%-61.4%-27.7%--19.3%-18.2%15.5%40.2%
ROCE % -68.4%-33.2%-18.8%--12.4%-4.4%5.0%11.1%

Shareholding Pattern

Insiders
3.40%
Institutions
108.87%
Public Float
112.70%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 15.32% 5.29M $355.71M
2 FMR, LLC 14.75% 5.10M $342.47M
3 Vanguard Portfolio Management LLC 5.55% 1.92M $128.99M
4 Vanguard Capital Management LLC 4.28% 1.48M $99.33M
5 State Street Corporation 3.82% 1.32M $88.67M
6 Invesco Ltd. 3.00% 1.04M $69.75M
7 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 2.72% 939.52K $63.14M
8 Nomura Asset Management International Inc 2.56% 885.84K $59.53M
9 Goldman Sachs Group Inc 2.51% 866.28K $58.21M
10 Geode Capital Management, LLC 2.43% 839.15K $56.39M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TMDX

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks